Back to Endocrinology
Endocrinologyv2016Evidence-Based

BeAM Value

Calculates the difference between bedtime and morning fasting blood glucose to guide prandial insulin therapy decisions in patients with type 2 diabetes

Clinical Input Parameters

mg/dL
Range: 40 — 600 mg/dL
mg/dL
Range: 40 — 600 mg/dL
Clinical Assessment
Awaiting Parameters
beam value
—mg/dL
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The BeAM Value is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within endocrinology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

BeAM Value = Bedtime glucose (mg/dL) - Morning fasting glucose (mg/dL)

Clinical Pearls & Practice Notes

  • The BeAM value helps identify patients with T2DM using basal insulin who need targeting of postprandial control rather than advancing basal insulin dose
  • Large BeAM (≥30 mg/dL) indicates need for prandial insulin supplementation
  • Negative BeAM (<0 mg/dL) is a contraindication for intensification of prandial insulin therapy
  • Should be used in conjunction with HbA1c and other diabetes management parameters
  • Requires consistent timing of glucose measurements (bedtime and morning fasting)

Evidence & Literature Citations

  1. Raz I, Wilson PW, Strojek K, Kowalska I, Bozikov V, Gitt AK, et al. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care. 2009 Mar;32(3):381-6.
  2. Blonde L, Merilainen M, Karwe V, Raskin P; TITRATE Study Group. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study. Diabetes Obes Metab. 2009 Jun;11(6):623-31.
  3. Garber AJ, King AB, Del Prato S, Sreenan S, Balci MK, Muñoz-Torres M, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012 Apr 21;379(9825):1498-507.

Score Interpretation Ranges

High BeAM30 – 1000 pts

Large BeAM value (≥30 mg/dL)

Medium/Low BeAM0 – 29 pts

Medium/Low BeAM value (0-29 mg/dL)

Negative BeAM-1000 – -1 pts

Negative BeAM value (<0 mg/dL)

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.